These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12514432)

  • 1. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
    Javia LR; Rosenberg SA
    J Immunother; 2003; 26(1):85-93. PubMed ID: 12514432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
    Takahashi T; Kuniyasu Y; Toda M; Sakaguchi N; Itoh M; Iwata M; Shimizu J; Sakaguchi S
    Int Immunol; 1998 Dec; 10(12):1969-80. PubMed ID: 9885918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells.
    Zhang X; Koldzic DN; Izikson L; Reddy J; Nazareno RF; Sakaguchi S; Kuchroo VK; Weiner HL
    Int Immunol; 2004 Feb; 16(2):249-56. PubMed ID: 14734610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
    J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.
    Thornton AM; Shevach EM
    J Immunol; 2000 Jan; 164(1):183-90. PubMed ID: 10605010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ CD25+ [corrected] regulatory T cells render naive CD4+ CD25- T cells anergic and suppressive.
    Qiao M; Thornton AM; Shevach EM
    Immunology; 2007 Apr; 120(4):447-55. PubMed ID: 17244157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
    Maker AV; Attia P; Rosenberg SA
    J Immunol; 2005 Dec; 175(11):7746-54. PubMed ID: 16301685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population.
    Taams LS; Smith J; Rustin MH; Salmon M; Poulter LW; Akbar AN
    Eur J Immunol; 2001 Apr; 31(4):1122-31. PubMed ID: 11298337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.
    Itoh M; Takahashi T; Sakaguchi N; Kuniyasu Y; Shimizu J; Otsuka F; Sakaguchi S
    J Immunol; 1999 May; 162(9):5317-26. PubMed ID: 10228007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.
    Zheng G; Wang B; Chen A
    J Immunol; 2004 Aug; 173(4):2428-34. PubMed ID: 15294956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+CD25+ T lymphocytes in human tonsils suppress the proliferation of CD4+CD25- tonsil cells.
    Simark-Mattsson C; Dahlgren U; Roos K
    Scand J Immunol; 2002 Jun; 55(6):606-11. PubMed ID: 12028564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses.
    Venken K; Thewissen M; Hellings N; Somers V; Hensen K; Rummens JL; Stinissen P
    J Immunol Methods; 2007 Apr; 322(1-2):1-11. PubMed ID: 17368474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.
    Dieckmann D; Plottner H; Berchtold S; Berger T; Schuler G
    J Exp Med; 2001 Jun; 193(11):1303-10. PubMed ID: 11390437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.
    Stephens LA; Mottet C; Mason D; Powrie F
    Eur J Immunol; 2001 Apr; 31(4):1247-54. PubMed ID: 11298351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloantigen-specific T suppressor-inducer and T suppressor-effector cells can be activated despite blocking the IL-2 receptor.
    Tan P; Anasetti C; Martin PJ; Hansen JA
    J Immunol; 1990 Jul; 145(2):485-8. PubMed ID: 1973183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow-derived dendritic cells reverse the anergic state of CD4+CD25+ T cells without reversing their suppressive function.
    Brinster C; Shevach EM
    J Immunol; 2005 Dec; 175(11):7332-40. PubMed ID: 16301639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.
    Hilchey SP; De A; Rimsza LM; Bankert RB; Bernstein SH
    J Immunol; 2007 Apr; 178(7):4051-61. PubMed ID: 17371959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
    Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
    Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
    Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.